Cite
HARVARD Citation
Powderly, J. et al. (n.d.). 373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2. Journal for immunotherapy of cancer. p. A398. [Online].